Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2021-11-17 Capital/Financing Update
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus related to a common stock offering by Apellis Pharmaceuticals, Inc. It includes detailed information about the securities offered, underwriting, risk factors, use of proceeds, and other offering details. The document references registration fees under the Securities Act of 1933 and is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing related to securities offerings. This type of document is a capital markets filing related to fundraising and issuance of new shares, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high due to clear identification of offering details and registration fee calculations.
2021-11-17 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to a $300 million common stock offering by Apellis Pharmaceuticals, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, dividend policy, and company overview. The document references SEC Rule 424(b)(5), which pertains to prospectus supplements filed in connection with securities offerings. The content focuses on the terms and conditions of the stock offering, underwriting details, and regulatory disclaimers typical of a capital raising document. There is no indication of financial statements, audit reports, earnings releases, or other report types. This document fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2021-11-15 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-08 English
PRIMARY DOCUMENT
Director's Dealing
2021-11-02 English
PRIMARY DOCUMENT
Director's Dealing
2021-10-27 English
PRIMARY DOCUMENT
Director's Dealing
2021-10-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.